Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 3/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11099597 | 1.00 | HTR2B (0.47) | HTR2BHTR3AHRH4ALOX15AAK1 | |
| SCHEMBL18322608 | 1.00 | HTR2B (0.47) | HTR2BHTR3AHRH4ALOX15AAK1 | |
| Water SCHEMBL29258021 | 0.98 | HTR2B (0.46) | HTR2BHTR3AHRH4ALOX15AAK1 | |
| SCHEMBL1901089 | 0.98 | HTR2B (0.48) | HTR2BHTR3AHRH4ALOX15AAK1 | |
| SCHEMBL1899026 | 0.94 | HTR2B (0.48) | HTR2BHTR3AHRH4ALOX15AAK1 | |
| SCHEMBL1767358 | 0.90 | — | — | |
| SCHEMBL18322464 | 0.83 | HTR2B (0.41) | HTR2BHTR3AHRH4ALOX15AAK1 | |
| SCHEMBL3709300 | 0.83 | HTR2B (0.46) | HTR2BALOX15TAAR1TERT | |
| SCHEMBL1299385 | 0.83 | HRH3 (0.46) | HTR2BHRH4ALOX15TAAR1 | |
| SCHEMBL18322692 | 0.81 | HTR2B (0.45) | HTR2BALOX15TAAR1TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| CN-108112251-B | NRF2 modulators | 葛兰素史克知识产权发展有限公司 | 2021-03-05 | — | — | CN | disclosed |
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-10604509-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-31 | — | — | US | disclosed |
| US-10604509-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-31 | — | — | US | disclosed |
| US-20200079759-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-03-12 | — | — | US | disclosed |
| CN-108112251-A | NRF2 conditioning agents | 葛兰素史克知识产权发展有限公司 | 2018-06-01 | — | — | CN | disclosed |
| EP-3307739-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016202253-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016202253-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
| CN-102387992-B | Molecular sieve and correlation technique and structure directing agent | 加利福尼亚技术学院 | 2016-07-06 | — | — | CN | disclosed |
| CN-102387992-A | Molecular sieves and related methods and structure directing agents | CALIFORNIA INST OF TECHN | 2012-03-21 | — | — | CN | disclosed |
| EP-1370533-A2 | IMIDIAZOLE DERIVATIVES AND THEIR USE AS AGONISTS SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | Allergan, Inc. (US) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002076950-A2 | IMIDIAZOLE DERIVATIVES AND THEIR USE AS AGONISTS SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-0821675-A1 | NOVEL HYDROXAMIC ACID AND AMINO-CARBOXYLATE COMPOUNDS AS METALLOPROTEASE AND TNF INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033176-A1 | NOVEL HYDROXAMIC ACID AND AMINO-CARBOXYLATE COMPOUNDS AS METALLOPROTEASE AND TNF INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604509-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | HTR2B 2077/4885HTR3A 2486/4885HRH4 2024/4885 |
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | HTR2B 2564/4885HTR3A 2561/4885HRH4 1708/4885 |
| US-20200079759-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | HTR2B 2564/4885HTR3A 2561/4885HRH4 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.